欧盟法规
ECHA物质C&L通报上下游产品
3-(三氟甲氧基)苯甲酸 3-(Trifluoromethoxy)Benzoic Acid 1014-81-9合成工艺路线路线简述
- 1014-81-9 = 86270-03-3
反应条件:1.1 Reagents: Oxalyl Chloride Solvents: Dichloromethane; 0 °C; 2 H,Rt
标题:Visible-Light-Induced Oxazoline Formations From N-Vinyl Amides Catalyzed By An Ion-Pair Charge-Transfer Complex
作者:Sun,Rui; Et Al
参考文献:Acs Catalysis 日期:2021 卷标:11(18) 页码:11762-11773]
1014-81-9 = 86270-03-3
反应条件:1.1 Reagents: Oxalyl Chloride Catalysts: Dimethylformamide Solvents: Dichloromethane; 0 °C; 3 H,Rt
标题:Pharmaceutical-Oriented Methoxylation Of Aryl C(Sp 2 )-H Bonds Using Copper Catalysts
作者:Zhang,Guofu; Et Al
参考文献:Synlett 日期:2018 卷标:29(11) 页码:1451-1554]
1014-81-9 = 86270-03-3
反应条件:1.1 Reagents: Oxalyl Chloride Catalysts: Dimethylformamide Solvents: Dichloromethane; 0 °C; 3 H,Rt
标题:Pharmaceutical-Oriented Iron-Catalyzed Ethoxylation Of Aryl C(Sp2)-H Bonds With Cobalt Co-Catalyst
作者:Zhang,Guofu; Et Al
参考文献:Chemistryselect 日期:2018 卷标:3(34) 页码:9803-9806
3-(三氟甲氧基)苯甲酸置于氯化亚砜体系中,化学反应 2.0H,反应生成 3-(三氟甲氧基)苯甲酰氯
参考文献:从铅到药物候选者:3-(苯基乙炔基)-1 H-吡唑并[3,4-D]嘧啶-4-胺衍生物作为治疗三阴性乳腺癌的药物的优化
标题:从铅到药物候选者:3-(苯基乙炔基)-1 H-吡唑并[3,4-D]嘧啶-4-胺衍生物作为治疗三阴性乳腺癌的药物的优化
摘要:本文中,我们报告了针对先前公开的src抑制剂化合物1进行结构优化的复杂过程,该化合物在体外和体内均显示出对三阴性乳腺癌(tnbc)的高治疗能力,但具有相当大的毒性.合成了一系列的3-(苯基乙炔基)-1 H-吡唑并[3,4-D]嘧啶-4-胺衍生物.最终基于体外细胞的表型筛选,以及体内测定和结构-活性关系(sar)研究最终导致了n-(3-((4-氨基-1-(反式-4-羟基环己基)-1 H)的发现-吡唑并[3,4-D]嘧啶-3-基)乙炔基)-4-甲基苯基)-4-甲基-3-(三氟甲基)苯甲酰胺(13An).13An是一种多激酶抑制剂,可有效抑制src(ic 50 = 0.003μm),Kdr(ic 50 = 0.032μm)和几种参与mapk信号转导的激酶.该化合物在体外和体内均显示出有效的抗tnbc活性,并具有非常好的药代动力学特性和低毒性.还研究了抗tnbc的作用机理.总体而言,本研究获
DOI:10.1021/acs.Jmedchem.6B00943
海关参考信息
- 2905110000-甲醇
2912110000-甲醛
2912210000-苯甲醛
2903110000-一氯甲烷及氯乙烷 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2011301143-A1
优先权日:2009-02-23
标题 :Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
发明人:ISABEL ELISE; LACHANCE NICOLAS; LECLERC JEAN-PHILIPPE; LEGER SERGE; OBALLA RENATA M; POWELL DAVID; RAMTOHUL YEEMAN K; ROY PATRICK; TRANMER GEOFFREY K; ASPIOTIS RENEE; LI LIANHAI; MARTINS EVELYN
权利人:ISABEL ELISE; LACHANCE NICOLAS; LECLERC JEAN-PHILIPPE; LEGER SERGE; OBALLA RENATA M; POWELL DAVID; RAMTOHUL YEEMAN K; ROY PATRICK; TRANMER GEOFFREY K; ASPIOTIS RENEE; LI LIANHAI; MARTINS EVELYN
摘要:Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, Câ•?CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.
专利号:US-8372971-B2
优先权日:2004-08-25
标 题:Heterocyclic compounds and methods of use
发明人:WRASIDLO WOLFGANG; DNEPROVSKAIA ELENA
权利人:TARGEGEN INC; WRASIDLO WOLFGANG; DNEPROVSKAIA ELENA
摘要:Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.